Research & Development
ReviR Therapeutics' RTX-117 receives FDA Rare Pediatric Disease Designation for Charcot-Marie-Tooth disease
27 August 2026 - Clinical-stage biotechnology company ReviR Therapeutics announced on Wednesday that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to ...
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic GEA eligible for ZIIHERA
27 August 2026 - Swiss healthcare company Roche (SIX: RO, ROG; OTCQX: RHHBY) announced on Wednesday that it has received FDA approval for expanded use of its PATHWAY HER2 (4B5) and VENTANA HER2 Dual I...
Annovis Bio schedules corporate update webinar for next week
26 August 2026 - Annovis Bio Inc (NYSE:ANVS), a Phase 3 clinical-stage biotechnology company developing an investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer�...
Cellenkos' CK0803 granted US FDA Fast Track designation for ALS
26 August 2026 - Cellenkos Inc, a clinical-stage biotechnology company developing tissue-directed, cord blood-derived T-regulatory (Treg) cell therapies, announced on Tuesday that the US Food and Drug...
FDA approves Johnson & Johnson's IMAAVY (nipocalimab-aahu) to treat warm autoimmune haemolytic anaemia
25 August 2026 - Healthcare products company Johnson & Johnson (NYSE:JNJ) announced on Monday that the US Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu) for the treatmen...
Labcorp to offer FDA-cleared pTau-217 blood test for Alzheimer's assessment
24 August 2026 - US laboratory services company Labcorp Holdings, Inc. (NYSE: LH) announced on Monday that, following US Food and Drug Administration clearance, it will offer the Elecsys pTau-217 test...